Mycrodose Therapeutics‘ CEO Chad Conner and Nova Mentis Life Science Corp’s Marvin Hausman discuss the new partnership the two groups have formed to to treat neuroinflammatory disorders, such as fragile X syndrome and autism spectrum disorder with psychedelics.
Category
Published in Proactive Investors